Preview

Научно-практическая ревматология

Расширенный поиск

Легочная артериальная гипертензия при системных заболеваниях соединительной ткани

https://doi.org/10.14412/1995-4484-2015-69-77

Полный текст:

Аннотация

В лекции рассматривается проблема одного из редких проявлений системных заболеваний – легочной артериальной гипертензии. Указывается необходимость ранней диагностики, тщательной дифференциальной диагностики, верификации диагноза с применением инвазивных способов оценки центральной гемодинамики. Представлена модель скрининга больных с системной склеродермией, упрощающая определение показаний для назначения методов, позволяющих верифицировать диагноз. Описаны современные подходы к лекарственной терапии, обсуждаются вопросы улучшения выживаемости пациентов с этой прогностически неблагоприятной патологией.

Об авторе

А. В. Волков
ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34А
Россия

заведующий лабораторией инструментальной диагностики ФГБНУ НИИР им. В.А. Насоновой, канд. мед. наук 



Список литературы

1. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138(6):1383–94. DOI: 10.1378/chest.10-0260

2. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376–87. DOI: 10.1378/chest.09-1140

3. Yang X, Mardekian K, Sanders KN, et al. Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol. 2013;32(10):1519–31. DOI: 10.1007/s10067-013-2307-2

4. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis. 2013;72(11):1747–55. DOI: 10.1136/annrheumdis-2013-204424

5. Amigues JM, Cantagrel A, Abbal M, Mazieres B. Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. J Rheumatol. 1996; 23(12):2055–62.

6. Launay D, Sitbon O, Hachulla E, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis. 2013;72(12):1940–6. DOI: 10.1136/annrheumdis-2012-202489

7. Avouac J, Airo P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol. 2010;37(11):2290–8. DOI: 10.3899/jrheum.100245

8. Iudici M, Codullo V, Giuggioli D, et al. Pulmonary hypertension in systemic sclerosis: prevalence, incidence and predictive factors in a large multicentric Italian cohort. Clin Exp Rheumatol. 2013;31(2 Suppl 76):31–6.

9. Mathai SP, Hassoun PM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin. 2012;8(3):413–25. DOI: 10.1016/j.hfc.2012.04.001

10. Gü ndü z OH, Fertig N, Lucas M, Medsger TA Jr. Systemic sclerosis with renal crisis and pulmonary hypertension: a report of eleven cases. Arthritis Rheum. 2001;44(7):1663–6. DOI: 10.1002/1529-0131(200107)44:7<1663::AID-ART290>3.0.CO;2C

11. Launay D, Mouthon L, Hachulla E, et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol. 2007;34(5):1005–11.

12. Чазова ИЕ, Авдеев СН, Царева НА и др. Клинические рекомендации по диагностике и лечению легочной гипертонии. Терапевтический архив. 2014;86(9):4–23 [Chazova IE, Avdeev SN, Tsareva NA, et al. Clinical guidelines for the diagnosis and treatment of pulmonary hypertension. Terapevticheskii arkhiv = Therapeutic Archive. 2014;86(9):4–23 (In Russ.)].

13. Schwaiger JP, Khanna D, Gerry Coghlan J. Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. Eur Respir Rev. 2013;22(130):515–25. DOI: 10.1183/09059180.00006013

14. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48(2):516–22. DOI: 10.1002/art.10775

15. Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford). 2004;43(4):461–6. DOI: 10.1093/rheumatology/keh067

16. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52(12):3792–800. DOI: 10.1002/art.21433

17. Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: Assessing the Spectrum of Pulmonary hypertension Identified at a REferral Centre. Eur Respir J. 2012;39(4):945–55. DOI: 10.1183/09031936.00078411

18. Gü nther S, Jais X, Maitre S, et al. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. Arthritis Rheum. 2012;64(9):2995–3005. DOI: 10.1002/art.34501

19. Dorfmuller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol. 2007;38(6):893–902. DOI: 10.1016/j.humpath.2006.11.022

20. Badesch DB, McGoon MD, Barst RJ, et al. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009;36(10):2244–9. DOI: 10.3899/jrheum.081277

21. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425–34. DOI: 10.7326/0003-4819-1326-200003210-00002

22. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18. DOI: 10.1056/NEJMoa1213917

23. Coghlan JC, Denton CP, Grü nig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340–9. DOI: 10.1136/annrheumdis-2013-203301

24. Kovacs G, Maier R, Aberer E, et al. Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med. 2009;180(9):881–6. DOI: 10.1164/rccm.200904-0563OC

25. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S55–66. DOI: 10.1016/j.jacc.2009.04.011

26. Saggar R, Khanna D, Shapiro S, et al. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study. Arthritis Rheum. 2012;64(12):4072–7. DOI: 10.1002/art.34614

27. Hoeper M, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42–50. DOI: 10.1016/j.jacc.2013.10.032

28. Saggar R, Khanna D, Furst DE, et al. Exercise-induced pulmonary hypertension associated with systemic sclerosis. Arthritis Rheum. 2010;62:3741–50. DOI: 10.1002/art.27695

29. Kovacs G, Maier R, Aberer E, et al. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum. 2012;64(4):1257–62. DOI: 10.1002/art.33460

30. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30(4):394–403. DOI: 10.1093/eurheartj/ehp022

31. Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J. 2011;75(11):2668–74. DOI: 10.1253/circj.CJ-11-0473

32. Mathai S, Hassoun P. Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Curr Opin Rheum. 2009;21(6):642–8. DOI: 10.1097/BOR.0b013e3283307dc8

33. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119–23. DOI: 10.1016/S01406736(01)06250-X

34. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903. DOI: 10.1056/NEJMoa012212

35. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57. DOI: 10.1056/NEJMoa050010

36. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010–9. DOI: 10.1161/CIRCULATIONAHA.107.742510

37. Launay D, Sitbon O, Le Pavec J, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoid or sildenafil. Rheumatology. 2010:49(3):490–500. DOI: 10.1093/rheumatology/kep398

38. Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax. 2005;60(2):1025–30.DOI: 10.1136/thx.2005.040618

39. Мартынюк ТВ, Зыков КА, Антонова ОЮ и др.Влияние бозентана на клинический статус и клеточное звено иммунитета у больных с идиопатической легочной гипертензией. Терапевтический архив. 2013;85(1):25–31 [Martyniuk TV, Zykov KA, Antonova OYu, et al. Effect of bosentan on the clinical status and cellular immunity of patients with idiopathic pulmonary hypertension. Terapevticheskii arkhiv = Therapeutic Archive. 2013;85(1):25–31 (In Russ.)].

40. Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007;34(12):2417–22.

41. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425–34. DOI: 10.7326/0003-4819-1326-200003210-00002

42. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70(1):32–8. DOI: 10.1136/ard.2010.130658

43. Nguyen VA, Eisendle K, Gruber I, et al. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study. Rheumatology (Oxford). 2010;49(3):583–7. DOI: 10.1093/rheumatology/kep413

44. Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Int Med. 1994;120(3):199–206. DOI: 10.7326/00034819-120-3-199402010-00004

45. Scorza R, Caronni M, Mascagni B, et al. Effect of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized controlled study. Clin Exp Rheum. 2001;19(5):503–8.

46. Airo P, Rossi M, Scarsi M, et al. Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group. Clin Exp Rheumatol. 2007; 25(5):722–36.


Для цитирования:


Волков А.В. Легочная артериальная гипертензия при системных заболеваниях соединительной ткани. Научно-практическая ревматология. 2015;53(1):69-77. https://doi.org/10.14412/1995-4484-2015-69-77

For citation:


Volkov A.V. PULMONARY ARTERIAL HYPERTENSION IN CONNECTIVE TISSUE DISEASES. Rheumatology Science and Practice. 2015;53(1):69-77. (In Russ.) https://doi.org/10.14412/1995-4484-2015-69-77

Просмотров: 655


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)